title: Significance of plasma chromogranin A determination in neuroendocrine tumour (NET) diagnosis.
abstract: The secretory nature of NETs implies the determination of the CgA concentration as a standard marker. The concentration of CgA in plasma correlates with the degree of histopathological differentiation, tumor stage, and is an essential prerequisite for therapy. A retrospective analysis of the results of the plasma CgA concentrations in relation to histopathological and clinical findings (type of NET according to the WHO classification, severity of disease based on the presence of metastases and clinical symptoms) as well as somatostatin receptor scintigraphy was performed in 41 patients with NET. The patients were treated in The Regional Oncology of Lublin from February 2005 to May 2008. Data from the literature and results of this study suggest the use of CgA in the diagnosis and prognosis of NET. Plasma CgA concentration analysed together with histopathological assessment of tumor and the clinical picture is a useful marker in the diagnosis of neuroendocrine tumours. High plasma CgA concentrations may indicate the presence of highly-differentiated NET (WDNEC), and also may indicate the presence of tumor metastasis. The highest CgA concentrations were observed in patients with neuroendocrine tumors associated with carcinoid symptoms and the presence of metastases to the liver.
authors.affiliation: Department of Biochemistry Diagnostics, Medical University of Lublin, Lublin, Poland. donicahelena@gmail.com
authors.forename: H
authors.initials: H
authors.lastname: Donica
authors.forename: A
authors.initials: A
authors.lastname: Malecha-Jędraszek
authors.forename: E
authors.initials: E
authors.lastname: Strosławska
authors.forename: A
authors.initials: A
authors.lastname: Burska
authors.forename: F
authors.initials: F
authors.lastname: Szubstarski
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D002276:Carcinoid Tumor / Q000175:diagnosis / Q000473:pathology; D053379:Chromogranin A / Q000097:blood*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D018358:Neuroendocrine Tumors / Q000175:diagnosis* / Q000473:pathology; D011379:Prognosis; D012189:Retrospective Studies
chemical_list: D014408:Biomarkers, Tumor; D053379:Chromogranin A